All Episodes
Pathfinders in Biopharma — 62 episodes
What's driving biotech's latest rally?
Dyne Therapeutics pioneers direct drug delivery to muscle and CNS
How it feels in the eye of an M&A bidding war
Why the MFN price battle is heading for court, not legislature
4DMT targets global retina market with long-lasting genetic treatment
Big-value deals set the pace in healthcare M&A
Is this finally the breakthrough moment for psychedelic therapies?
No biotech bubble – but can the sector’s rally persist through 2026?
MindMed: Rethinking brain health with psychedelic therapy
Funding the future of retinal health with Eyepoint
How Blackstone Life Sciences is bridging the innovation gap
Compass trials mark a milestone moment for the psychedelics sector
Cidara’s pursuit of universal flu protection with a single dose
Ocular Therapeutix’ bold vision to redefine retinal disease treatment
PTC Therapeutics: Building a durable company to benefit patients
BioAge is translating insights from the science of aging into new medicines
Uncertainty reigns, but opportunity persists for biotech’s 2025
Unlocking Biotech’s Potential: Strategies for Navigating Public and Private Market Investments
Former Investor Who Chose Broadcasting Over Biotech ETFs
Can AI Solve Molecule Mysteries that will Unlock Simpler Drug Discovery?
Shots-on-Goal Licensing Company Aims for Breakthroughs
Why Biopharma Needs to Tell Better Stories on Novel Drugs
Venture capital velocity: What’s driving renewed momentum in biotech?
Pharma Understands Phase One Data – But Does the Market?
Davern Capital sees GLP-1 Opportunities Beyond Obesity
Betting on Healthcare’s Future Hits – and Misses
Innovation and an Aging Population Drive MedTech
Biopharma Investors See Opportunities in Targeted Treatments and Gene Editing
Biotech with a Mission to Target Unmet Cancer Needs
The M&A Pool Set to Accelerate Biotech Innovation
How PIPEs finally unblocked biotech’s funding flows
Disruptive Forces in Healthcare: Why HCIT is finally set to bounce back
Will the Biotech Rebound Run into Pricing Policy Obstacles?
Few IPOs but plenty of follow-on for biotech in 2023
U.S. Outlook: Will the US economy achieve a soft landing in 2024?
Raising Venture Capital: A New Playbook for A New Era in Biotech
ECM: Robust End to Year, Despite Previous Volatility
Biotech Halftime Report: A Winding Road Ahead
The Urgent Need to Address the Youth Mental Health Landscape
Website Traffic Reveals Biopharma Sales Trends
When to Call it Quits: VCs Making Tough Decisions in a Tough Market
How Biotech M&A is Redefining the Strategic Landscape
Healthcare Should Get Ready for ‘Fast and Furious’ M&A
Innovation and Growth: Key Ingredients to Healthcare M&A
Biotech M&A Booms, But Have Buyouts Reached a Tipping Point?
Global Blood Therapeutics Commitment to Sickle-Cell Innovation
Is This the Breakthrough Moment for Genetic Medicine?
The Hidden Revolution Set to Turn US Healthcare on its Head
The Big Picture for Biotech
Why Biopharma Investment Requires a Different Mindset
The Optimism Behind the Biopharma Market
Biotech Investors: How to Find Value in a Bear Market
A call to action: Global Blood Therapeutics on tackling orphan disease
Ionis: Raising The Bar For ESG
Biotech and Big Pharma: Blueprint for Successful Partnership
What’s Material in ESG for Biopharma Firms?
Inside Track: Behind the Scenes of a Major Biotech SPAC
Biotech SPACs: A new route to going public
5AM Ventures: Fueling the Next Generation of Innovators
Vida Ventures: Powering Breakthroughs in Biopharma
Biotech IPOs: Navigating the New Landscape
Biotech IPOs: New Steps to Success on the Road to Going Public